LOS ANGELES, Aug. 12, 2013 /PRNewswire/ -- Today Grifols was honored at the California State Legislature by state Senator Kevin de Leon (D-Los Angeles) and Assembly Member Jimmy Gomez (D- East Los Angeles) marking the 10th Anniversary of the Company's establishment of its U.S. headquarters in Los Angeles, and a decade of conducting business in California and improving the health and well-being of people around the world.
Grifols, a global healthcare company based in Barcelona, Spain, produces life-saving plasma medicines out of human plasma for people with rare, chronic and life-threatening conditions. California is one of Grifols' largest and most important business hubs with Los Angeles housing the company's U.S. headquarters and its 350,000 square-foot state-of-the-art manufacturing facility. Grifols acquired the El Sereno facility in East Los Angeles in 2003. Since then, it has completed a large scale $135 million dollar capital investment project that includes the construction of a new 95,000 square foot, intravenous immune globulin (IVIG) production facility.
"Grifols is proud of the Company's significant investments in the state, reflecting our strong commitment to California and to meeting the needs patients who rely on life-saving plasma therapies well into the future," commented Greg Rich, CEO of Grifols Inc.
"Grifols is pleased to employ over 1,200 Californians in high-quality skilled jobs and continues to foster a thriving workforce in Los Angeles and across the state," said Willie Zuniga, President of Grifols Biologicals Inc., who has also developed strong partnerships with Los Angeles Trade Technical College, California State University, Los Angeles, and the Wilshire-Metro WorkSource Center to promote education, job training and skills development for area residents.
In addition to the Los Angeles site, Grifols operates a 140,000 square-foot climate-controlled plasma warehouse and final packaging center in the City of Industry and owns and operates six plasma donation centers from San Diego to Bakersfield, where Californians donate their plasma for the production of life-saving medicines.
Grifols is a global healthcare company with a 70-year legacy of improving people's health and well-being through the development of life-saving plasma medicines, hospital pharmacy products, and diagnostic technology for clinical use.
As a leading producer of plasma medicines, Grifols has a presence in more than 100 countries and is the world leader in plasma collection, with 150 plasma donation centres across the US. Grifols is committed to increasing patient access to its life-saving plasma medicines through significant manufacturing expansions and the development of new therapeutic applications of plasma proteins. The company is headquartered in Barcelona, Spain, and employs more than 11,000 people worldwide.
In 2012, Grifols' sales exceeded 2,620 million euros. The company's class A shares are listed on the Spanish Stock Exchange, where they form part of the Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ: GRFS). For more information, visit www.grifols.com.